Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics to Report Second Quarter 2020 Financial Results
12:00pm, Monday, 03'rd Aug 2020
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report its financial results f
Akebia Therapeutics Inc (NASDAQ:AKBA) Shares Sold by Dupont Capital Management Corp
06:30am, Monday, 03'rd Aug 2020
Dupont Capital Management Corp cut its holdings in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 8.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
Tricida Provides Regulatory Update on Veverimer
12:00am, Wednesday, 15'th Jul 2020
Tricida Provides Regulatory Update on Veverimer
Akebia Initiates Vadadustat Study In Covid-19 Patients
02:32pm, Tuesday, 14'th Jul 2020
Akebia Therapeutics (AKBA) has announced the initiation of an investigator-sponsored study evaluating the use of vadadustat as a potential therapy to prevent and lessen the severity of acute respirato
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced the initiation of an investigator-sp
Akebia Therapeutics (NASDAQ:AKBA) Lowered to Hold at ValuEngine
07:08am, Tuesday, 14'th Jul 2020
ValuEngine lowered shares of Akebia Therapeutics (NASDAQ:AKBA) from a buy rating to a hold rating in a research report released on Monday morning, ValuEngine reports. Several other brokerages also rec
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
12:00am, Wednesday, 08'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)
AbbVie Inc (NYSE: ABBV)...
What Is The Ownership Structure Like For Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
01:37pm, Monday, 06'th Jul 2020
If you want to know who really controls Akebia Therapeutics, Inc. (NASDAQ:AKBA), then you'll have to look at the...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Thursday, 02'nd Jul 2020
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase
How R&D Expenses Can Help You Pick Outperforming Stocks
12:13pm, Thursday, 02'nd Jul 2020
A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet
AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board
12:00am, Wednesday, 01'st Jul 2020
AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Company
Chief Khalsa Diwan passes budget of Rs 147 crore for 2020-21
04:09pm, Tuesday, 30'th Jun 2020
The 117-year-old apolitical Sikh organisation Chief Khalsa Diwan (CKD) passed approximately Rs 147 crore budget for 2020-21 in the meetings of executive committee and General...
Akebia Therapeutics (AKBA) Receives a Buy from Needham - Markets
02:54pm, Monday, 29'th Jun 2020
Needham analyst Chad Messer assigned a Buy rating to Akebia Therapeutics (AKBA – Research Report) today and set a price
